Curative Biotechnology, Inc.
CUBT
Rank in Stocks
#30227
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused... Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Share Price
$0.6591
Last synced: 2026-11-17
Market Cap
$5.44M
Change (1 day)
-22.46%
Change (1 year)
-48.51%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Curative Biotechnology, Inc. (CUBT)
Category
Healthcare
EPS for Curative Biotechnology, Inc. (CUBT)
EPS as of June 2026 TTM: $-0.41
According to Curative Biotechnology, Inc.'s latest financial reports, its current EPS (TTM) is $-0.41. At the end of 2025 the company had an EPS of 0.00, an increase over its 2024 EPS of $-0.60.
EPS history for Curative Biotechnology, Inc. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.41 | -99.50% |
| 2025 | 0.00 | -99.50% |
| 2024 | $-0.60 | -54.55% |
| 2023 | $-1.32 | -10.20% |
| 2022 | $-1.47 | -73.94% |
| 2021 | $-5.64 | -97.26% |
| 2020 | $-205.50 | -137,100.00% |
| 2019 | $0.15 | -1,100.00% |
| 2018 | $-0.02 | 0.00% |
| 2017 | $-0.02 | 0.00% |
| 2016 | $-0.02 | -116.67% |
| 2015 | $0.09 | -400.00% |
| 2014 | $-0.03 | 0.00% |
| 2013 | $-0.03 | -81.82% |
| 2012 | $-0.17 | -74.42% |
| 2011 | $-0.65 | -83.46% |
| 2010 | $-3.90 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 117.07% |
US
|
|
| $15.66 | -3,919.51% |
US
|
|
| $-7.07 | 1,624.39% |
US
|
|
| $-5.29 | 1,190.24% |
AU
|
|
| $12.73 | -3,205.41% |
BE
|
Questions about Curative Biotechnology, Inc.'s earnings per share (EPS)
What is Curative Biotechnology, Inc.'s earnings per share (EPS)?
Curative Biotechnology, Inc.'s earnings per share (EPS) over the last twelve months is $-0.41, as of Jun 2026.
What was Curative Biotechnology, Inc.'s earnings per share (EPS) in 2025?
In 2025, Curative Biotechnology, Inc.'s earnings per share (EPS) was 0.00, compared with $-0.60 in 2024.
How has Curative Biotechnology, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Curative Biotechnology, Inc.'s earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2020 ($-205.50).
How does Curative Biotechnology, Inc.'s earnings per share (EPS) compare with similar companies?
Curative Biotechnology, Inc.'s earnings per share (EPS) ($-0.41) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.